α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
More effective treatments for metastatic prostate cancer (mPC) are needed as disease progression remains universal. 177Lu-PSMA-617 radiopharmaceutical therapy (RPT)—Pluvicto (Novartis)—was first approved for the treatment of castration-resistant prostate cancer (PC) based on the landmark VISION
Authors
- Clemens Kratochwil (ORCID: https://orcid.org/0000-0003-1334-8260)
- Oliver Sartor
- Stephen Rose (ORCID: https://orcid.org/0000-0003-1558-6297)
- Louise Emmett (ORCID: https://orcid.org/0000-0002-4895-7384)
- Shahneen Kaur Sandhu (ORCID: https://orcid.org/0000-0002-8660-4475)
- Anna Karmann
- Ken Herrmann
Institutions
- Advantest (Singapore) (SG)
- Heidelberg University (DE)
- Sydney College of Divinity (AU)
- Peter MacCallum Cancer Centre (AU)
- University Hospital Heidelberg (DE)
- St Vincent's Hospital Sydney (AU)
- St Vincent’s Private Hospital Sydney (AU)
- Essen University Hospital (DE)
- St Vincent's Clinic (AU)
- Louisiana Cancer Research Center (US)
- West German Heart and Vascular Center Essen (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-10-03
- DOI
- https://doi.org/10.2967/jnumed.125.270940
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00